{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:12:42Z","timestamp":1784988762253,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Retroperitoneal fibrosis (RPF) is a rare disease characterized by the presence of fibroinflammatory tissue that surrounds the abdominal aorta and the iliac arteries and often entraps the ureters. Hydronephrosis is a common complication of RPF, however, its clinical features and outcomes have not been well elucidated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 115 RPF-related hydronephrosis patients have been recruited from 9 clinical centers in China since March 2010. They were followed up until death or September 2021, whichever came first.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age at diagnosis was 58.83\u202f\u00b1\u202f12.13\u202fyears, and 80 patients (69.57%) were men. The median disease duration was 3.00 (1.00, 9.00) months. Renal impairment was observed in 88.35% of the patients, and 49.57% showed bilateral ureteral involvement. Elevated ESR and CRP were presented in 80.28 and 62.02% of the patients, respectively. Overall, 28.21% (11\/39) of the patients had increased IgG4 levels, and 41.38% (12\/29) showed positive pathological IgG4 staining (IgG4<jats:sup>+<\/jats:sup>\/IgG<jats:sup>+<\/jats:sup>\u202f\u2265\u202f40% or IgG4<jats:sup>+<\/jats:sup>\u202f\u2265\u202f10\/HPF). Among them, three patients were diagnosed as IgG4RD. After 60.43\u202f\u00b1\u202f34.53\u202fmonths of follow-up, 36 patients had poor prognosis, which was associated with severe kidney impairment, bilateral hydronephrosis and inflammation status (elevated ESR and IgG) at diagnosis by case\u2013control study. eGFR and creatinine were independent risk factors after adjusting for all other significant associations (<jats:italic>p<\/jats:italic>\u202f=\u202f0.002 and <jats:italic>p<\/jats:italic>\u202f=\u202f0.067, respectively). Glucocorticoid-based therapy could reduce the time of stenting, decrease the need for long-term ureteral stenting\/percutaneous nephrostomy (PNS)\/ureterolysis, increase the rate of mass shrinkage, and reduce the new requirement of hemodialysis compared to surgery-only strategy for RPF-related hydronephrosis patients in need of renal drainage, but did not reduce new-onset renal atrophy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Severity of kidney dysfunction and inflammation status were related to the poor prognosis of hydronephrosis induced by RPF. More efficient interventions and strategies are needed to further improve outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1435870","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:25:58Z","timestamp":1733718358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of retroperitoneal fibrosis-related hydronephrosis and its risk factors for poor prognosis: a multi-center retrospective cohort study in Chinese patients"],"prefix":"10.3389","volume":"11","author":[{"given":"Hongyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ut-kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-bo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-wu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-wu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/rai2.12058","article-title":"Histological evolution of IgG4 related disease","volume":"2","author":"Sathiavageesan","year":"2022","journal-title":"Rheumatol Autoimmun"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(04)16100-X","article-title":"Asbestos exposure as a risk factor for retroperitoneal fibrosis","volume":"363","author":"Uibu","year":"2004","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.juro.2010.09.105","article-title":"Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry","volume":"185","author":"Brandt","year":"2011","journal-title":"J. Urol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/iju.12234","article-title":"Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction","volume":"21","author":"Mertens","year":"2014","journal-title":"Int. J. Urol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1053\/j.ajkd.2009.04.019","article-title":"Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment","volume":"54","author":"Swartz","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/03009742.2018.1497700","article-title":"Long-term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study","volume":"48","author":"Zhao","year":"2019","journal-title":"Scand. J. Rheumatol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s10157-019-01759-w","article-title":"Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis","volume":"23","author":"Moriconi","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1053\/j.ajkd.2019.04.020","article-title":"Idiopathic retroperitoneal fibrosis: long-term risk and predictors of relapse","volume":"74","author":"Raffiotta","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/ndt\/gfaa083","article-title":"Idiopathic retroperitoneal fibrosis: an update for nephrologists","volume":"36","author":"Raglianti","year":"2021","journal-title":"Nephrol. Dial. Transplant"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","article-title":"Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2015101110","article-title":"Idiopathic retroperitoneal fibrosis","volume":"27","author":"Vaglio","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4065\/mcp.2010.0663","article-title":"Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes","volume":"86","author":"Kermani","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/MD.0b013e3181afc439","article-title":"Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation","volume":"88","author":"Scheel","year":"2009","journal-title":"Medicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0002-9343(03)00056-1","article-title":"Evidence of autoimmunity in chronic periaortitis: a prospective study","volume":"114","author":"Vaglio","year":"2003","journal-title":"Am. J. Med."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/ndt\/gfl228","article-title":"Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and\/or medical approaches","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol. Dial. Transplant"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1136\/annrheumdis-2013-203267","article-title":"Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis","volume":"72","author":"Alberici","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2011-200148","article-title":"Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis","volume":"71","author":"Binder","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000357814","article-title":"Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis","volume":"93","author":"Brandt","year":"2014","journal-title":"Urol. Int."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1007\/s00330-005-0136-7","article-title":"Percutaneous nephrostomy and antegrade ureteral stenting: technique-indications-complications","volume":"16","author":"Hausegger","year":"2006","journal-title":"Eur. Radiol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.amjmed.2003.08.033","article-title":"Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases","volume":"116","author":"Marcolongo","year":"2004","journal-title":"Am. J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.juro.2007.03.057","article-title":"Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis","volume":"178","author":"Scheel","year":"2007","journal-title":"J. Urol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5414\/CNP69260","article-title":"Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil","volume":"69","author":"Swartz","year":"2008","journal-title":"Clin. Nephrol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7326\/0003-4819-144-2-200601170-00007","article-title":"Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis","volume":"144","author":"Van Bommel","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/ckj\/sfv148","article-title":"Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy","volume":"9","author":"Van der Bilt","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e12631","DOI":"10.1097\/MD.0000000000012631","article-title":"Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis","volume":"97","author":"Wallwork","year":"2018","journal-title":"Medicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.urology.2021.03.002","article-title":"Including medical Management in the Urologic Approach to idiopathic retroperitoneal fibrosis","volume":"152","author":"Santiago","year":"2021","journal-title":"Urology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ejim.2012.11.010","article-title":"Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis","volume":"24","author":"Van Bommel","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/ard-2022-223736","article-title":"Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis","volume":"82","author":"Gao","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.19723\/j.issn.1671-167X.2020.06.013","article-title":"Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports","volume":"52","author":"Liu","year":"2020","journal-title":"Da Xue Xue Bao"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/03009742.2017.1363280","article-title":"Idiopathic retroperitoneal fibrosis: a cross-sectional study of 142 Chinese patients","volume":"47","author":"Liao","year":"2018","journal-title":"Scand. J. Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1435870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:26:01Z","timestamp":1733718361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1435870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":31,"alternative-id":["10.3389\/fmed.2024.1435870"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1435870","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"article-number":"1435870"}}